EFG Asset Management North America Corp. Trims Position in Natera, Inc. $NTRA

EFG Asset Management North America Corp. trimmed its position in shares of Natera, Inc. (NASDAQ:NTRA) by 6.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,911 shares of the medical research company’s stock after selling 2,110 shares during the period. EFG Asset Management North America Corp.’s holdings in Natera were worth $5,134,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Rakuten Investment Management Inc. purchased a new position in shares of Natera in the third quarter valued at about $34,096,000. SWS Partners grew its position in shares of Natera by 11.8% during the third quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock worth $7,572,000 after purchasing an additional 4,980 shares in the last quarter. Vontobel Holding Ltd. raised its stake in Natera by 192.5% during the 3rd quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock valued at $1,373,000 after purchasing an additional 5,614 shares during the period. Orion Porfolio Solutions LLC lifted its holdings in Natera by 68.8% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock worth $2,051,000 after purchasing an additional 4,946 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its stake in Natera by 277.8% in the 2nd quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock worth $4,498,000 after purchasing an additional 19,576 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Trading Down 0.1%

Shares of NASDAQ NTRA opened at $241.39 on Tuesday. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36. The firm’s 50-day moving average price is $234.89 and its 200-day moving average price is $192.16. The stock has a market capitalization of $33.39 billion, a price-to-earnings ratio of -105.41 and a beta of 1.62.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The company had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. During the same period in the previous year, the firm earned ($0.26) earnings per share. The company’s revenue was up 34.7% compared to the same quarter last year. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

NTRA has been the topic of several research analyst reports. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Morgan Stanley lifted their price target on shares of Natera from $220.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, December 1st. Piper Sandler increased their price objective on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Wells Fargo & Company lifted their target price on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a report on Monday, December 15th. Finally, Guggenheim increased their price target on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus target price of $245.50.

Insider Activity

In related news, Director Roelof Botha sold 75,000 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the sale, the director owned 1,154,198 shares in the company, valued at approximately $272,529,231.76. This represents a 6.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 23,205 shares of Natera stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70. Following the transaction, the insider directly owned 144,992 shares of the company’s stock, valued at $34,035,422.08. The trade was a 13.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 501,436 shares of company stock worth $111,775,823. Company insiders own 5.63% of the company’s stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.